Adult-onset Still's disease

被引:81
作者
Kádár, J [1 ]
Petrovicz, E [1 ]
机构
[1] Szent Laszlo Hosp Budapest, Favarosi Szent Laszlo Korhaz, Dept Internal Med 6, H-1097 Budapest, Hungary
来源
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2004年 / 18卷 / 05期
关键词
Still's disease; seronegative; fever; signs; therapy;
D O I
10.1016/j.berh.2004.05.004
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder of unknown etiology and pathogenesis. AOSD is a rare condition, usually presenting with high fever accompanied by systemic manifestations. The disease is a heterogeneous pathological entity with a range of etiologies, manifestations and prognosis. There is no single diagnostic test for AOSD; rather, the diagnosis is based upon clinical criteria such as arthralgia, fever, skin rash, lymphadenopathy, and hepatosplenomegaly. Determination of the procalcitonin level and the biological response to empirical corticosteroid therapy generally helps the diagnosis, while immune-serology, as a 'screening' test, will not add meaningful information in most cases. Treatment consists of anti-inflammatory medications. Non-steroid anti-inflammatory drugs have limited efficacy, corticosteroid therapy and disease-modifying antirheumatic drugs are usually required. Novel therapeutic approaches, such as anti-tumor necrosis factor blockade and stem cell transplantation, are promising. In this chapter we present clinical and laboratory parameters of IS patients diagnosed with AOSD at our institution between 1997 and 2003, and review the literature.
引用
收藏
页码:663 / 676
页数:14
相关论文
共 50 条
[1]
Cavagna L, 2001, CLIN EXP RHEUMATOL, V19, P329
[2]
CUSH JJ, ADULT ONSET STILLS D
[3]
DEBENEDETTI F, 1997, CURRENT OPINION RHEU, V38, P428
[4]
Diamond JR, 1997, J NEPHROL, V10, P253
[5]
Dino O, 1996, J RHEUMATOL, V23, P784
[6]
DOMINGUES RB, 2003, ARCH NEUROPSYCHIATRY, V6, P259
[7]
Fautrel B, 2001, J RHEUMATOL, V28, P322
[8]
Fautrel B, 1999, J RHEUMATOL, V26, P373
[9]
Safety and efficacy of disease-modifying anti-rheumatic agents - Focus on the benefits and risks of etanercept [J].
Fleischmann, R ;
Iqbal, I ;
Nandeshwar, P ;
Quiceno, A .
DRUG SAFETY, 2002, 25 (03) :173-197
[10]
Honjoh H, 1995, CLIN NEPHROL, V44, P400